10-Q Filing

Astrana Health, Inc. CIK: 1083446 Q1 2016

Filing Information

Form Type	10-Q
Accession Number	`0001144204-16-119141`
Period End Date	20160630
Filing Date	20160815
Fiscal Year	2016
Fiscal Period	Q1
XBRL Instance	ameh-20160630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 34 Cash Flow Statement 62

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.89M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$601.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $769,000 and $601,000 at June 30, 2016 and March 31, 2016, respectively	`AccountsReceivableNetCurrent`	$4.00M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $769,000 and $601,000 at June 30, 2016 and March 31, 2016, respectively	`AccountsReceivableNetCurrent`	$3.39M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$769.00K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$581.21K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$315.23K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$20.05K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$20.50K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$293.83K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$509.01K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.56M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.35M	USD	Point-in-time
Deferred financing costs	`DeferredFinanceCostsNoncurrentNet`	$37.93K	USD	Point-in-time
Deferred financing costs	`DeferredFinanceCostsNoncurrentNet`	-	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.34M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.25M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$530.00K	USD	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$530.00K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	5.88M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.00M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$2.26M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	5.88M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$2.35M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.00M	shares	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$216.44K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$213.68K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$19.57M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$17.32M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.57M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.25M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$2.51M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$2.67M	USD	Point-in-time
Note and line of credit	`NotesAndLinesOfCreditPayableCurrent`	$188.76K	USD	Point-in-time
Note and line of credit	`NotesAndLinesOfCreditPayableCurrent`	$176.26K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.43M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$6.94M	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$1.99M	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$2.81M	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$728.88K	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$762.46K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$43.48K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$43.48K	USD	Point-in-time
Total liabilities	`Liabilities`	$11.02M	USD	Point-in-time
Total liabilities	`Liabilities`	$9.74M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B); 1,111,111 issued and outstanding Liquidation preference of $9,999,999	`TemporaryEquityCarryingAmountAttributableToParent`	$7.08M	USD	Point-in-time
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B); 1,111,111 issued and outstanding Liquidation preference of $9,999,999	`TemporaryEquityCarryingAmountAttributableToParent`	$7.08M	USD	Point-in-time
Common Stock, par value $0.001; 100,000,000 shares authorized, 5,998,518 and 5,876,852 shares issued and outstanding as of June 30, 2016 and March 31, 2016, respectively	`CommonStockValue`	$6.00K	USD	Point-in-time
Common Stock, par value $0.001; 100,000,000 shares authorized, 5,998,518 and 5,876,852 shares issued and outstanding as of June 30, 2016 and March 31, 2016, respectively	`CommonStockValue`	$5.88K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapital`	$23.52M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapital`	$23.90M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-28.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-30.00M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-1.27M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-2.20M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$2.71M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$2.74M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$503.85K	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.47M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$19.57M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$17.32M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`Revenues`	$12.37M	USD	1 Quarter
Net revenues	`Revenues`	$10.20M	USD	1 Quarter
Cost of services	`CostOfServices`	$7.57M	USD	1 Quarter
Cost of services	`CostOfServices`	$10.13M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.84M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.24M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$63.75K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$164.66K	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$11.87M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$14.13M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.76M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.66M	USD	1 Quarter
Interest expense	`InterestExpense`	$360.40K	USD	1 Quarter
Interest expense	`InterestExpense`	$2.66K	USD	1 Quarter
Gain (loss) on change in fair value of warrant and conversion feature liabilities, net	`GainLossOnDerivativeInstrumentsNetPretax`	$-213.72K	USD	1 Quarter
Gain (loss) on change in fair value of warrant and conversion feature liabilities, net	`GainLossOnDerivativeInstrumentsNetPretax`	$822.22K	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$101.00K	USD	1 Quarter
Other income	`OtherNonoperatingIncomeExpense`	$1.97K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$821.53K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-473.12K	USD	1 Quarter
Loss before (benefit) provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-940.93K	USD	1 Quarter
Loss before (benefit) provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-2.14M	USD	1 Quarter
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$92.69K	USD	1 Quarter
(Benefit) provision for income taxes	`IncomeTaxExpenseBenefit`	$-41.55K	USD	1 Quarter
Net loss	`ProfitLoss`	$-899.38K	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.23M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$251.86K	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$415.88K	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-1.32M	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-2.48M	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.51	USD	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.91M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	4.86M	shares	1 Quarter

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-899.38K	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.23M	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	-	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$167.50K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$63.75K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$164.66K	USD	1 Quarter
Deferred income tax	`DeferredIncomeTaxExpenseBenefit`	-	USD	1 Quarter
Deferred income tax	`DeferredIncomeTaxExpenseBenefit`	$3.06K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$83.85K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$247.72K	USD	1 Quarter
Amortization of deferred financing costs	`AdjustmentForAmortization`	$37.93K	USD	1 Quarter
Amortization of deferred financing costs	`AdjustmentForAmortization`	$29.91K	USD	1 Quarter
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	$115.61K	USD	1 Quarter
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$-213.72K	USD	1 Quarter
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$822.22K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-108.83K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$774.09K	USD	1 Quarter
Other receivables	`IncreaseDecreaseInOtherReceivables`	$120.15K	USD	1 Quarter
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-265.98K	USD	1 Quarter
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$14.75K	USD	1 Quarter
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-453.00	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$215.18K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$-20.70K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-2.76K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-6.57K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$790.61K	USD	1 Quarter
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-317.45K	USD	1 Quarter
Deferred financing cost	`IncreaseDecreaseInDeferredCharges`	-	USD	1 Quarter
Deferred financing cost	`IncreaseDecreaseInDeferredCharges`	$-513.35K	USD	1 Quarter
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$33.58K	USD	1 Quarter
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	-	USD	1 Quarter
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-158.67K	USD	1 Quarter
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-112.90K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-528.35K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-2.27M	USD	1 Quarter
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$163.51K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	-	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-163.51K	USD	1 Quarter
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	-	USD	1 Quarter
Principal payments on lines of credit	`RepaymentsOfLinesOfCredit`	$12.50K	USD	1 Quarter
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$595.42K	USD	1 Quarter
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$450.00K	USD	1 Quarter
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	1 Quarter
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	$132.00K	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-330.50K	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-595.42K	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.12M	USD	1 Quarter
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.76M	USD	1 Quarter
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.89M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.89M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.51M	USD	Point-in-time
Interest paid	`InterestPaid`	$100.96K	USD	1 Quarter
Interest paid	`InterestPaid`	$7.14K	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaid`	$16.40K	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaid`	$32.20K	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.